Volume 3, Issue 9

Treatment Paradigms and DMT Choices

In this issue:

What factors should most influence the choice of a disease-modifying therapy for a patient with diagnosed RRMS? Which treatment paradigm is likely to provide the most benefit? How much weight should each person’s demographic, clinical, and paraclinical characteristics be given in the decision-making process? What about the aggressiveness of the disease and potential long-term disability outcomes? And how much say should the patient have in determining which treatment will best meet their needs?  

Those are some of the questions addressed by Drs. Scott Newsome, Olwen Murphy, and Anne Damian from the Johns Hopkins University and Dr. Yujie Wang from the University of Washington in their expert analysis of the recent literature in this issue of eMultipleSclerosis Review. 

Learning objectives:

  • Describe the available treatment paradigms (escalation approach, early highly effective therapy approach, and personalized approach incorporating individual prognostic factors) for people with MS.
  • Compare the potential risk profiles that may be associated with specific highly effective therapies vs modestly effective therapies.

Authors:

Scott Newsome, DO, MSCS, FAAN, FANA
Scott Newsome, DO, MSCS, FAAN, FANA

Associate Professor of Neurology
Director, Neurosciences Consultation and Infusion Center at Green Spring Station
Director, Stiff Person Syndrome Center
Co-Director, Multiple Sclerosis Experimental Therapeutics Program
Co-Director, Johns Hopkins Neuroimmunolgy Clinical Fellowship Program
Member, Miller-Coulson Academy of Clinical Excellence
Johns Hopkins Hospital
Division of Neuroimmunology and Neuroinfectious Diseases
Baltimore, MD

Yujie Wang, MD
Yujie Wang, MD
Acting Assistant Professor of Neurology
University of Washington
Seattle, WA
Adjunct Assistant Professor of Neurology
Johns Hopkins University
Baltimore, MD
Anne Damian Yacoub, MD
Anne Damian Yacoub, MD

Assistant Professor of Neurology
Johns Hopkins University School of Medicine
Baltimore, MD

Olwen C. Murphy, MB, BCH, MRCP
Olwen C. Murphy, MB, BCH, MRCP

Neurology fellow
Johns Hopkins University School of Medicine
Baltimore, MD

Program Directors:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Pavan Bhargava, MBBS, MD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Lisa Fox, PA-C, MPAS

Department of Neurology
Johns Hopkins Hospital
Baltimore, MD

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: March 3, 2021
Expiration date: March 2, 2023